Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. (RETA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
reta · stock forecast · 10 analysts (3M) · FMP · updated Mar 26, 2024
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Hold
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$115
Consensus
$62.67
-63.6% upside
Low
$27.00
Median: $46 · Last Close: $172.36
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$62.67
-63.6% upside
High Target
$115
-33.3%
Low Target
$27
-84.3%
Current Price
$172.36
as of today
Based on analyst price targets, the RETA stock price prediction for the next 12 months ranges from $27 to $115. The consensus RETA price forecast of $62.67 implies -63.6% upside from the current price of $172.36.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $172.29 | ↓ 0.04% |
1-day model range: $172.24–$172.35. Peak: $172.35 (-0.04%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RETA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-08-15 | Cantor Fitzgerald | Maintains | Neutral→Neutral |
| 2023-08-14 | Cantor Fitzgerald | Maintains | Neutral→Neutral |
| 2023-08-01 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2023-08-01 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
| 2023-07-31 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2023-07-31 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2023-07-31 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
| 2023-07-31 | Ladenburg Thalmann | Downgrade ↓ | Buy→Neutral |
| 2023-07-31 | Baird | Maintains | Outperform→Outperform |
| 2023-07-30 | Ladenburg Thalmann | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on Reata Pharmaceuticals, Inc. (RETA) stock. Of the recent 102 rating actions, 4 were upgrades and 16 were downgrades. 10 analysts currently cover RETA.
Analyst Recommendation Trends
RETA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 6 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast RETA EPS of $— for the current fiscal year, based on estimates from 0 analysts. The RETA revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RETA stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RETA price target is $62.67 (-63.6% upside), with an analyst consensus of Hold.
The RETA short-term stock prediction for tomorrow is $172.29 (-0.04%).
Reata Pharmaceuticals, Inc. trades on NASDAQ under the ticker RETA. The RETA stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 40% of covering analysts.
Frequently asked questions
RETA forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month RETA price target is $62.67, with a high forecast of $115.00 and a low of $27.00. The median price target is shown in the chart above when available. This implies -63.6% potential upside from the current price of $172.36.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.